S&P Upgrades ICU Medical to 'BB' on Debt Reduction and Stronger Metrics

S&P Global Ratings has upgraded ICU Medical Inc.'s (NASDAQ:ICUI) corporate credit rating to 'BB' from 'BB-', with a stable outlook. The ratings agency cited the company's strengthened credit metrics, driven by consistent debt reduction and solid operating performance.

Rationale for the Upgrade

The upgrade reflects ICU Medical's significant progress in deleveraging its balance sheet. According to S&P, the company's adjusted leverage declined to 3.1x as of the second quarter, and its reported leverage stood at 2.28x as of June 30.

This improvement was facilitated by strategic debt repayments. The company utilized key cash sources to lower its obligations, including:

• Approximately $200 million from the 2025 sale of a 60% stake in its IV solutions business to pay down its term loan.
• An additional $50 million of free operating cash flow to repay debt in the second quarter of 2026.

S&P's Outlook and Projections

Ad

S&P Global Ratings assigned a stable outlook, reflecting its expectation that ICU Medical will maintain adjusted debt-to-EBITDA below 4x. The agency projects the company's adjusted leverage will be approximately 3.2x in 2026 and 2027.

While S&P forecasts a 2.5% revenue decline for the full-year 2026, due to the deconsolidation of the IV solutions business, it anticipates a return to growth of approximately 4.5% in 2027. Margins are also expected to improve to between 15.5% and 16.0% in 2026. The ratings agency noted that once ICU Medical reaches its internal net leverage target of 2x, it is likely to increase share repurchases.

Operational Context

ICU Medical's underlying business has shown positive momentum, with organic revenue growing 6% in the second quarter. The company attributed this growth to competitive wins, accelerated installations of its infusion systems, and new product launches.

However, the company continues to manage regulatory matters. While a 2021 FDA warning letter was successfully closed earlier this year, a separate warning letter issued in 2025 concerning certain pump products remains outstanding, according to the S&P report.